Advertisement
ESMC vs HBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESMC is a Hold and HBIO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ESMC’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).
- ESMC’s FA Score: 0 green, 5 red.
- HBIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ESMC’s TA Score shows that 2 TA indicator(s) are bullish while HBIO’s TA Score has 5 bullish TA indicator(s).
- ESMC’s TA Score: 2 bullish, 4 bearish.
- HBIO’s TA Score: 5 bullish, 5 bearish.
Price Growth
ESMC (@Medical/Nursing Services) experienced а +5.63% price change this week, while HBIO (@Pharmaceuticals: Other) price change was +6.67% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.36%. For the same industry, the average monthly price growth was -4.79%, and the average quarterly price growth was +5.70%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.10%. For the same industry, the average monthly price growth was +0.50%, and the average quarterly price growth was +6.41%.
Reported Earning Dates
HBIO is expected to report earnings on Mar 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (+0.36% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.10% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ESMC | HBIO | ESMC / HBIO | |
| Capitalization | 1.25M | 25.8M | 5% |
| EBITDA | 687K | -46.8M | -1% |
| Gain YTD | 34.661 | -70.517 | -49% |
| P/E Ratio | 2.40 | N/A | - |
| Revenue | 12.9M | 88.8M | 15% |
| Total Cash | 541K | 7.44M | 7% |
| Total Debt | 516K | 43.3M | 1% |
ESMC | HBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 35 | 99 | |
PRICE GROWTH RATING 1..100 | 65 | 39 | |
P/E GROWTH RATING 1..100 | 100 | 2 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ESMC's Valuation (83) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that ESMC’s stock grew similarly to HBIO’s over the last 12 months.
ESMC's Profit vs Risk Rating (91) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that ESMC’s stock grew similarly to HBIO’s over the last 12 months.
ESMC's SMR Rating (35) in the Medical Specialties industry is somewhat better than the same rating for HBIO (99) in the Biotechnology industry. This means that ESMC’s stock grew somewhat faster than HBIO’s over the last 12 months.
HBIO's Price Growth Rating (39) in the Biotechnology industry is in the same range as ESMC (65) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to ESMC’s over the last 12 months.
HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ESMC (100) in the Medical Specialties industry. This means that HBIO’s stock grew significantly faster than ESMC’s over the last 12 months.
| ESMC | HBIO | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 82% |
| Stochastic ODDS (%) | 1 day ago 88% | 3 days ago 71% |
| Momentum ODDS (%) | 1 day ago 81% | 3 days ago 79% |
| MACD ODDS (%) | 1 day ago 82% | 3 days ago 83% |
| TrendWeek ODDS (%) | 1 day ago 77% | 3 days ago 76% |
| TrendMonth ODDS (%) | 1 day ago 75% | 3 days ago 75% |
| Advances ODDS (%) | N/A | 3 days ago 72% |
| Declines ODDS (%) | 23 days ago 74% | 8 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 90% | 3 days ago 81% |
| Aroon ODDS (%) | N/A | 3 days ago 89% |
Advertisement
ESMC and
Correlation & Price change
A.I.dvisor tells us that ESMC and MDRSF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESMC and MDRSF's prices will move in lockstep.
| Ticker / NAME | Correlation To ESMC | 1D Price Change % | ||
|---|---|---|---|---|
| ESMC | 100% | +5.96% | ||
| MDRSF - ESMC | 21% Poorly correlated | N/A | ||
| MASI - ESMC | 9% Poorly correlated | +1.76% | ||
| FONR - ESMC | 8% Poorly correlated | -0.81% | ||
| MDT - ESMC | 8% Poorly correlated | +0.34% | ||
| HBIO - ESMC | -1% Poorly correlated | -6.41% | ||
More | ||||
HBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.
| Ticker / NAME | Correlation To HBIO | 1D Price Change % | ||
|---|---|---|---|---|
| HBIO | 100% | +2.40% | ||
| IRMD - HBIO | 46% Loosely correlated | +2.11% | ||
| A - HBIO | 37% Loosely correlated | +1.41% | ||
| RVTY - HBIO | 36% Loosely correlated | -0.19% | ||
| MTD - HBIO | 35% Loosely correlated | +0.19% | ||
| NEOG - HBIO | 34% Loosely correlated | -0.92% | ||
More | ||||